<DOC>
	<DOC>NCT00069849</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.</brief_summary>
	<brief_title>A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>INCLUSION CRITERIA: Current diagnosis of probable Alzheimer's disease. ADAScog score of at least 12 and MMSE score of 10 to 26. Nonsmoker Must have legally authorized representative and a reliable caregiver. The caregiver and legally authorized representative may be the same person. Fluent in English. EXCLUSION CRITERIA: Use of cholinesterase inhibitors or any other drugs to treat Alzheimer's disease in the last 6 weeks. Has clinically significant or uncontrolled medical condition other than Alzheimer's disease. Nursing home resident.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>